RecruitingHepatorenal SyndromeAcute Kidney Injury
Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome
Eligible age
18+ yrs
Accepts
All genders
Locations
7 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study aims to evaluate the safety, tolerability and efficacy of R2R01 combined with terlipressin as compared to terlipressin alone in the treatment of patients with HRS-AKI
Sponsor: River 2 Renal Corp.
You may qualify if…
- ✓ 1. Patient is able to communicate well with the Investigator, understands and is willing to comply with all requirements of the study, and understands and signs the written informed consent form (ICF).
- ✓ 2. At least 18 years of age.
- ✓ 3. Cirrhosis and ascites.
- ✓ 4. AKI stage 2 or 3. AKI defined by any of the following: 1) increase in SCr (SCr) ≥ 0.3 mg/dl (or ≥ 26.5 micromolar/L) within 48 h, or 2) increase ≥ 50% in baseline SCr, which is known or presumed to have occurred within the prior seven days.
- ✓ 5. QLY SCr ≥ to 1.5 mg/dl.
- ✓ 6. No sustained improvement in renal function (less than 20% decrease in SCr and SCr =\> 1.5 mg/dL) after 48 h of diuretic withdrawal and the beginning of plasma volume expansion with albumin.
- ✓ 7. Female patients as well as female partners of male patients must be willing to avoid pregnancy for the duration of the study (\>90 days).
You may not qualify if…
- ✕ 1. Significant co-morbidities that in the opinion of the Investigator would preclude study participation.
- ✕ 2. QLY SCr level \> 5 mg/dL.
- ✕ 3. AKI stage 1.
- ✕ 4. ACLF stage 3.
- ✕ 5. Model for End-Stage Liver Disease (MELD) score \>35.
- ✕ 6. At least one event of large volume paracentesis (LVP) \> 4 Liters in the last 4 days before enrollment.
- ✕ 7. Current or recent (within 4 weeks) treatment with nephrotoxic drugs (e.g., aminoglycosides, amphotericin, cyclosporine, NSAIDS (e.g., ibuprofen, naproxen, celecoxib), significant exposure to radiographic contrast agents (large doses or multiple injections of iodinated contrast media).
- ✕ 8. Shock (hypovolemic-, cardiogenic-, or vasodilatory/distributive shock) with mean arterial blood pressure (MAP) ≤70 mmHg or systolic blood pressure ≤90 mmHg along with hypoperfusion.
Where it's recruiting
California
San Francisco
Georgia
Atlanta
Massachusetts
Boston
Minnesota
Rochester
Pennsylvania
Philadelphia
Tennessee
Nashville
Texas
Fort Worth
Source: ClinicalTrials.gov · NCT05875948 · last updated 2023-10-03